- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Dry powder for inhalation containing aclidinium bromide.
Chronic obstructive pulmonary disease
One inhalation of 322 micrograms aclidinium twice daily.
Additional Dosage Information
If a dose is missed the next dose should be taken as soon as possible. However, if it is nearly time for the next dose, the missed dose should not be taken.
Children under 18 years
Precautions and Warnings
Benign prostatic hyperplasia
Bladder outflow obstruction
Glucose-galactose malabsorption syndrome
Narrow angle glaucoma
New York Heart Association class III failure
New York Heart Association class IV failure
Within 6 months of a myocardial infarction
Not suitable for acute treatment of bronchospasm
Advise ability to drive/operate machinery may be affected by side effects
Ensure patient has a fast acting bronchodilator available
Check patient is using correct inhaler technique
Prolonged treatment may lead to dental caries
Discontinue if paradoxical bronchospasm occurs
Patient should seek medical advice if usual relief is diminished
Pregnancy and Lactation
Use aclidinium with caution during pregnancy.
The manufacturer recommends aclidinium is not used in pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus. Some studies in animals have shown foetotoxicity and maternal toxicity only at dose levels much higher than the maximum human exposure to aclidinium. At the time of writing there is limited human data available. Risks are unknown.
Aclidinium is contraindicated during breastfeeding.
The manufacturer advises discontinuing breastfeeding or discontinuing aclidinium. Animal studies have shown excretion of small amounts of aclidinium bromide and/or metabolites into milk. It is unknown whether aclidinium and/or its metabolites are excreted in human breast milk.
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: January 2021
Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 10th edition (2015) ed. Briggs, G., Freeman, R. Wolters Kluwer Health, Philadelphia.
Summary of Product Characteristics: Eklira Genuair 322 micrograms inhalation powder. AstraZeneca UK Ltd. Revised November 2019.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.